Spero Therapeutics, Inc. (SPRO): Revenue
$66.80M
Year ended 2025-12-31
$47.00M
Trailing 12 months to 2026-06-30
+7.7%
3-year compound annual growth
+48.2%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $66.80M | +39.2% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $47.98M | -53.8% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $103.78M | +94.0% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $53.51M | +193.1% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $18.26M | +95.7% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $9.33M | -48.6% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $18.15M | +357.6% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $3.97M | +100.4% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $1.98M | +490.7% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $335.0K | n/a | 2019-03-14, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $66.80M | +39.2% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $67.48M | +25.2% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $65.32M | -3.4% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $69.26M | -31.8% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $63.26M | +9.7% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $70.85M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $62.90M | +699.0% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $62.38M | +48.3% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $72.30M | +153.5% |
Compare SPRO, KURA, ENTA, RMTI side by side · Screen every company in Pharmaceutical Preparations ↗